Inhibikase (IKT) corrects Cabell option exercise price in Form 4/A

Rhea-AI Filing Summary

Form 4/A overview: Inhibikase Therapeutics (IKT) filed an amended Form 4 for President & Head of R&D Christopher Cabell. The filing corrects the exercise price to $2.97 on a previously reported stock-option grant covering 1,100,705 common shares originally awarded on Feb 21 2025 and expiring on Feb 21 2035. No other terms change: the options vest in three substantially equal tranches on the 2nd, 3rd and 4th anniversaries of the grant date, contingent on continued service. The amendment does not involve any share sales or purchases and therefore has no immediate cash impact on the company. It simply aligns the public record with the correct contractual terms, maintaining disclosure accuracy and avoiding potential misinterpretation of executive compensation.

Insights

Corporate Governance Analyst

TL;DR — Administrative correction; neutral impact.

The amendment fixes an erroneous strike price on Mr. Cabell’s large option grant. Because no new equity is issued and no transaction occurred, dilution and cash flow remain unchanged. Accurate disclosure is important, but the correction itself neither strengthens nor weakens Inhibikase’s governance profile. Investors should simply note the correct $2.97 strike and standard four-year vesting schedule when modeling potential future dilution.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cabell Christopher

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Head of R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/25/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.97(1)	02/21/2025		A		1,100,705		(2)	02/21/2035	Common Stock	1,100,705	$0	1,100,705	D

Explanation of Responses:

1. The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.

2. The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

	/s/ Mark Iwicki, attorney-in-fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Inhibikase (IKT) file an amended Form 4/A on July 2 2025?

The company corrected the exercise price of a stock-option grant to $2.97 for President Christopher Cabell.

How many options were affected by the correction in the IKT Form 4/A?

A total of 1,100,705 options were involved, all granted on February 21 2025.

What is the new exercise price for Christopher Cabell’s IKT options?

The amended exercise price is $2.97 per share.

When do the corrected IKT options vest?

They vest in three equal installments on the 2nd, 3rd and 4th anniversaries of February 21 2025.

Does the Form 4/A indicate any immediate share sales or purchases by the insider?

No. The filing only corrects the strike price; it reports no share sales or purchases.